# A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

> **NCT00422994** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** ropinirole dosing for up to 28 days

## Key facts

- **NCT ID:** NCT00422994
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422994, "A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00422994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*